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OBJECTIVES We investigated the vascular effects of candesartan in hypertensive patients.
BACKGROUND The renin-angiotensin system may contribute to atherogenesis through the promotion of
endothelial dysfunction. The plausible mechanisms are that angiotensin II promotes
superoxide anion generation, endothelial dysfunction, inflammation, and impaired fibrinoly-
sis. The effects of candesartan on these conditions have not been clearly observed.
METHODS We administered placebo or candesartan 16 mg daily during two months to 45 patients with
mild-to-moderate hypertension. This was a randomized, double-blind, placebo-controlled,
crossover study in design.
RESULTS Candesartan did not significantly change lipoprotein levels. However, compared with
placebo, candesartan significantly reduced plasma levels of malondialdehyde from 1.50 0.07
to 1.29  0.09 M (p  0.009); improved the percent flow-mediated dilator response to
hyperemia from 5.17 0.24 to 6.22 0.26% (p 0.001); and, furthermore, reduced plasma
levels of monocyte chemoattractant protein (MCP-1) from 213  8 to 190  7 pg/ml (p 
0.003), tumor necrosis factor-alpha from 2.93 to 2.22 pg/ml (p  0.026), and plasminogen
activator inhibitor type 1 from 74 4 to 53 4 ng/ml (p 0.001) but not C-reactive protein
(CRP), matrix metalloproteinase protein, and fibrinogen. There were no significant correla-
tions between these changes and reduction of systolic blood pressure (BP) (0.247  r 
0.195) and between these changes and reduction of diastolic BP (0.262 r 0.197). There
were no significant correlations between markers of inflammation and flow-mediated dilation
percent or reduction of oxidant stress (0.119  r  0.127). Furthermore, we observed no
significant correlations between CRP and MCP-1 levels (r  0.162).
CONCLUSIONS Inhibition of the angiotensin II type 1 (AT1) receptor in hypertensive patients reverses
endothelial dysfunction, measured as an improvement in flow-mediated dilation and
fibrinolysis and reduction of oxidant stress and inflammatory cytokines, suggesting that AT1
receptor blocker therapy has antiatherogenic effects. (J Am Coll Cardiol 2003;42:905–10)
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The Losartan Intervention For Endpoint Reduction in
Hypertension study (LIFE) demonstrated that losartan,
angiotensin II type 1 (AT1) receptor blocker, therapy
prevented or retarded the progression of coronary heart
disease. This study suggests benefits beyond reduction in
See page 911
blood pressure (BP) (1). Endothelial dysfunction of epicar-
dial coronary arteries precedes development of atheroscle-
rotic disease that is either angiographically apparent or of
sufficient obstructive severity to cause myocardial ischemia
and angina pectoris (2). Hypertensive patients have im-
paired functions of the endothelium, which is a marker of
future cardiovascular events (3). The vessel wall in endothe-
lial dysfunction may promote inflammation, plaque rupture,
and thrombus formation, which contribute to development
and clinical expression of atherosclerosis (4).
Recent experimental studies have confirmed that angio-
tensin II (AII) accelerates the development of atherosclero-
sis (5,6). The plausible mechanisms are that AII promotes
superoxide anion generation and endothelial dysfunction
(7,8). Angiotensin II activates nuclear transcription factor
(NFB) induced by oxidative stress (9). This effect is
mediated by AT1 receptor (10). Nuclear transcription factor
activates proinflammatory transcription factors and, thus,
stimulates the synthesis of protein products such as cell
adhesion molecules and chemokines (9,11,12). In hyperten-
sive patients AII infusion leads to a rapid increase in plasma
intercellular adhesion molecule-1 via an AT1 receptor-
dependent mechanism (13). Angiotensin II type 1 receptor
blocker could diminish intracellular production of super-
oxide anions via reduced activity of AII-dependent oxidases
in the endothelium and vascular smooth muscle (14,15),
thus protecting nitric oxide (NO) from oxidant degradation
to biologically inert or toxic molecules (4,16). Inhibition of
the production of superoxide anions could also limit the
oxidation of low-density lipoprotein (LDL), thus contrib-
uting to increased NO bioactivity by enhancing NO syn-
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thesis and limiting oxidative degradation of NO (4,16). In
this regard, AT1 receptor blocker inhibited LDL oxidation
and attenuated atherosclerosis independent of lowering BP
(17). In addition to improving vasomotor tone, increased
NO bioactivity within the vasculature may prevent activa-
tion of proinflammatory transcription factors and, thus,
reduce synthesis of protein products such as chemokines
(18). On the other hand, plasminogen activator inhibitor
type-1 (PAI-1) expression is affected by AII and mediated
by the AT1 receptor, and interestingly, PAI-1 expression
was suppressed by candesartan (19,20), in contrast with
losartan (21), showing no effects.
However, the effects of AT1 receptor blocker on
endothelium-dependent vasomotor responsiveness are con-
flicting in patients (22–25). Furthermore, the effects of AT1
receptor blockers on inflammation (26–31) and fibrinolysis
(31–34) are conflicting in patients. In this study, we inves-
tigated the potential benefit of candesartan, an AT1 recep-
tor blocker, on endothelium-dependent vasomotor respon-
siveness, oxidant stress, and markers of inflammation,
hemostasis, and plaque stability in hypertensive patients.
METHODS
Study population and design. Forty-seven patients with
mild-to-moderate hypertension participated in this study.
We used World Health Organization/International Society
of Hypertension definitions (35) for hypertension defined as
systolic and diastolic BP 140 or 90 mm Hg, respec-
tively. In order to minimize acute side effects to candesartan,
study medication was titrated from 8 to 16 mg upwards over
a two-week period if no hypotension (systolic BP100 mm
Hg) was noted. At the end of this time, participants were
receiving either placebo or candesartan per day. The patients
were seen, at a minimum, at 14-day intervals during the
study. None was diabetic or a current smoker. Forty-five of
47 patients tolerated candesartan at 16 mg to maintain a
systolic BP 100 mm Hg for 3 h after drug administration,
experiencing no adverse effects. One patient was hypoten-
sive, and the other suffered from a dry cough. Thus, data
from a total of 45 patients were analyzed. Baseline total
cholesterol, triglyceride, high-density lipoprotein choles-
terol, and LDL cholesterol levels were 209  8, 195  14,
49  2, and 116  7 mg/dl, respectively. Baseline systolic
and diastolic pressures were 165  2 and 101  1 mm Hg.
The mean age was 50  2 years, and 33 (73%) were male.
This was a randomized, double-blind, placebo-controlled,
crossover study in design. Study participants received pla-
cebo or candesartan 16 mg daily during two months, with
the second treatment period initiated upon completion of
the first treatment period (without washout phase). In order
to avoid effects from other drugs, no other medications were
allowed during the study period. The study was approved by
the Gil Hospital Institute Review Board, and all partici-
pants gave written, informed consent.
Laboratory assays. Blood samples for laboratory assays
were obtained at approximately 8:00 AM after overnight
fasting, at baseline, and at the end of each treatment period
and immediately coded so that investigators performing
laboratory assays were blinded to subject identity or study
sequence. Assays for lipids, plasma malondialdehyde
(MDA), monocyte chemoattractant protein (MCP)-1,
tumor necrosis factor (TNF)-alpha, matrix metallo-
proteinase protein (MMP)-9, PAI-1, and serum C-reactive
protein (CRP) were performed in duplicate by ELISA (R & D
Systems, Inc., Minneapolis, Minnesota; BIOXYTECH
LPO-586, OxisResearch, Portland, Oregon; BioPool, Ven-
tura, California; Rate nephelometry; IMMAGEO, Beck-
man Coulter, Brea, California), as previously described
(36–40). C-reactive protein levels were determined with an
immunonephelometry system according to methods de-
scribed by the manufacturer. The measurement range is 0.1
to 98 mg/dl. All samples from the same patient (batch
samples) were measured in blinded pairs on the same
ELISA kit to minimize run-to-run variability. The inter-
assay and intra-assay coefficients of variation were 6%.
Vascular studies. Imaging studies of the right brachial
artery were performed using a ATL HDI 3000 ultrasound
machine equipped with a 10-MHz linear-array transducer,
based on a previously published technique (36,37,39,40).
All images were transmitted to a personal computer via
Ethernet with DICOM format (Digital Imaging and Com-
munication in Medicine) and then saved on the hard disk of
a personal computer as a bitmap format. Arterial diameters
were measured with Image Tool for Windows version 2.0
(University of Texas Health Science Center, San Antonio,
Texas). Measurements were performed by two independent
investigators (D.K.J. and H.S.K.) blinded to the subject’s
identity and medication status. Measurements of maximum
diameter and percent flow-mediated dilation were made in
10 studies selected at random. The interobserver and in-
traobserver variability for repeated measurement of maxi-
mum diameter were 0.004  0.039 mm and 0.005  0.089
mm, respectively. The interobserver and intraobserver vari-
ability for repeated measurement of percent flow-mediated
dilation were 0.07  1.27% and 0.15  1.24%, respectively.
Statistical analysis. Data are expressed as mean SEM or
median (range: 25% to 75%). After testing data for normal-
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ity, we used the Student paired t or Wilcoxon signed rank
test to compare values after placebo and candesartan ther-
apies, as reported in Table 1. We decided to use the end of
a two-month treatment period without washout and the
second baseline. Indeed, we found no carryover effect in this
study (see Results section). Pearson correlation coefficient
analysis was used to assess associations between measured
parameters. We calculated that 30 subjects would provide
80% power for detecting an absolute increase of 2.1%
(  0.05, based on our previous studies) (39) flow-
mediated dilation of the brachial artery between baseline
and candesartan. A value of p  0.05 was considered
statistically significant.
RESULTS
To assess the possibility of a carryover effect from the initial
treatment periods to the next treatment period, we com-
pared the percent changes of: 1) the first treatment placebo,
and the second treatment placebo 2) the first treatment
candesartan and the second treatment candesartan, relative
to baseline values. There were no significant differences in
age and baseline values—vascular function (diameter and
flow) and markers of inflammation—between each group.
No significant differences were found in the above two
comparisons (data not shown).
Effects of therapies on BP and lipids. Compared with
placebo, candesartan therapy reduced systolic (160  2 vs.
140 2 mm Hg, p 0.001) and diastolic (99 1 vs. 87
1 mm Hg, p  0.001) BP after two months’ administration
of oral candesartan. Resting heart rate (83  1 vs. 84  1,
p  0.575) was similar after candesartan therapy. Cande-
sartan therapy did not change lipoprotein levels (Table 1).
Effects of therapies on malondialdehyde and vasomotor
function. Basal brachial artery diameter and forearm blood
flows were similar to those during placebo or candesartan
treatment periods, as were the peak brachial artery diame-
ters and forearm blood flows during reactive hyperemia and
the percent increase in flow during hyperemia (data not
shown). Compared with placebo, candesartan therapy sig-
nificantly reduced plasma levels of MDA and improved the
percent flow-mediated dilator response to hyperemia by
14  5% and 29  7%, respectively (p  0.009 and p 
0.001, respectively). The brachial artery dilator response to
nitroglycerin between each therapy was not significantly
different (p  0.296).
Effects of therapies on markers of inflammation.
Compared with placebo, candesartan therapy significantly
lowered plasma levels of MCP-1 by 9 3% and TNF-alpha
by 10  4% from the respective baseline levels (p  0.003
and p  0.026, respectively, Fig. 1). We observed that
patients with the highest baseline MCP-1 levels showed the
greatest extent of reductions with candesartan (r  0.363,
p  0.013). However, candesartan therapy did not signifi-
cantly lower serum levels of CRP (p  0.799).
Effects of therapies on markers of hemostasis and plaque
stability. Compared with placebo, candesartan therapy sig-
nificantly lowered plasma levels of PAI-1 by 21  5% from
the respective baseline levels (p  0.001; Fig. 2). However,
candesartan therapy did not significantly lower plasma levels
of antithrombin III, fibrinogen, and MMP-9 (p  0.284,
p  0.768, and p  0.282, respectively).
We investigated whether candesartan-induced changes in
the percent flow-mediated dilator response to hyperemia
Table 1. Effects of Placebo or Oral Candesartan on Lipids and
Endothelial Function in Hypertensive Patients
Placebo Candesartan
Lipids (mg/dl)
Total cholesterol 208  7 202  6
HDL cholesterol 50  2 51  3
LDL cholesterol 116  5 113  5
Triglycerides 203  22 193  19
Vasomotor function
Flow-mediated dilation (%) 5.17  0.24 6.22  0.26‡
Nitroglycerin dilation (%) 13.73  0.58 14.18  0.57
MDA (M) 1.50  0.07 1.29  0.09†
Inflammation
MCP-1 (pg/ml) 213  8 190  7†
TNF- (pg/ml) 2.93 (1.87–4.31) 2.22 (1.85–3.75)*
CRP (mg/dl) 0.16 (0.11–0.27) 0.17 (0.11–0.26)
Hemostasis
Antithrombin III (mg/dl) 28.8  0.5 29.0  0.5
PAI-1 (ng/ml) 74  4 53  4‡
Fibrinogen (mg/dl) 285  10 285  11
MMP-9 (ng/ml) 24.4  1.7 27.2  2.5
Data are expressed as means  SEM or median (25% to 75%). *p  0.05; †p  0.01;
‡p  0.001 vs. placebo.
CRP  C-reactive protein; HDL  high-density lipoprotein; LDL  low-
density lipoprotein; MCP  monocyte chemoattractant protein; MDA  malondi-
aldehyde; MMP  matrix metalloproteinase protein; PAI  plasminogen activator
inhibitor; TNF  tumor necrosis factor.
Figure 1. Compared with placebo, candesartan therapy significantly low-
ered plasma levels of monocyte chemoattractant protein-1 from the
respective baseline levels (p  0.003). Open circles  mean values.
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and serological markers of oxidant stress, inflammation, and
fibrinolysis were mediated by reduction of systolic or dia-
stolic BP after candesartan. There were no significant
correlations between these changes and reduction of systolic
BP (0.247  r  0.195) and between these changes and
reduction of diastolic BP (0.262  r  0.197). We also
investigated whether the candesartan-induced reduction in
serological markers of inflammation was mediated by im-
provement in NO bioactivity or reduction of oxidant stress.
There were no significant correlations (0.119  r 
0.127). Furthermore, despite an experimental study show-
ing a mechanism for the regulation of CRP and MCP-1
levels (41), we observed no significant correlations between
CRP and MCP-1 levels (r  0.162, p  0.307).
DISCUSSION
We observed that two months of candesartan therapy
significantly improved the percent flow-mediated dilator
response to hyperemia and reduced levels of oxidant stress
and inflammatory and impaired fibrinolysis markers in
hypertensive patients, independent of lipoprotein and BP
changes.
Our finding of improved endothelium-dependent vaso-
motor responsiveness is consistent with other groups’ results
(23–25). Thus, Schiffrin et al. (24) demonstrated that, in
contrast with atenolol, losartan corrected endothelial dys-
function in patients with essential hypertension, and Ghia-
doni et al. (25) also demonstrated similar improvement in
endothelial function with candesartan. We reasoned that
candesartan might improve endothelium-dependent vaso-
motor responsiveness by reducing oxidant stress and aug-
menting NO bioactivity, considering that AII is a potent
vasoconstrictor that also promotes oxidant stress. We ob-
served that two months of candesartan therapy significantly
reduced plasma levels of MDA, compared with placebo.
Although we did not measure prostaglandin F2, studies
have reported an excellent correlation between prostaglan-
din F2 and MDA levels (42,43).
In order to gain insight into mechanisms of potential
vasculoprotective effects of candesartan, we measured sur-
rogate markers for vascular inflammation. Inflammatory
cytokines secreted by macrophages and T lymphocytes can
modify endothelial function, smooth muscle cell prolifera-
tion, collagen degradation, and thrombosis (4,44). We
observed that candesartan therapy significantly reduced
plasma levels of MCP-1 and TNF-alpha but not CRP and
fibrinogen levels.
Tomita et al. (45) observed that inhibition of NO
synthesis with Nw-nitro-L-arginine methyl ester induced
inflammatory changes and MCP-1 expression in rat hearts
and vessels. Activated platelets stimulated MCP-1 produc-
tion in endothelial cells via an NFB-dependent mecha-
nism (46). On the other hand, experimental studies dem-
onstrated that AII activates NFB through AT1 and AT2
receptor stimulation (10) and induces MCP-1 expression in
cell culture (47); furthermore, candesartan appears to inhibit
the enhancement of MCP-1 expression in rats (48). How-
ever, the effects of AT1 receptor blockade on MCP-1 are
controversial in patients (29–31). For example, losartan at a
mean dose of 77 mg daily did not significantly alter the
levels of soluble cell adhesion molecules (consistent with our
previous findings [28]) or MCP-1 (29). However, cande-
sartan administered at 16 mg daily for six weeks significantly
reduced levels of soluble intercellular adhesion molecule-1
and MCP-1 in hypercholestrolemic patients (30,31), a
finding that is consistent with our current study. The
difference between losartan and candesartan may partly be
attributed to a tenfold stronger AT1 blocking effect of the
latter agent. We hypothesize that candesartan may reduce
plasma MCP-1 levels via inactivation of NF-B, due to an
improved bioactivity of NO, as shown by improvement in
flow-mediated dilation. However, we did not observe a
significant correlation between the changes in flow-
mediated dilation and plasma levels of MCP-1, a finding
that may be explained by the complex pathogenesis of
atherosclerosis involving multiple interactions and the rela-
tively small sample size ( error).
We also observed that candesartan reduced plasma levels
of TNF-alpha. Other studies have observed this effect in
patients with heart failure (26) and coronary artery disease
(27). Experimental studies demonstrated that CRP stimu-
lates the synthesis of MCP-1 (41). In the current study,
candesartan did not alter serum CRP levels, consistent with
other studies (27,28). We observed no correlations between
CRP levels and MCP-1 levels in humans.
Previous studies have shown that the AT1 receptor
Figure 2. Compared with placebo, candesartan therapy significantly low-
ered plasma levels of plasminogen activator inhibitor type-1 (PAI-1) from
the respective baseline levels (p  0.001). Open circles  mean values.
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blocker losartan partially blocks AII-induced PAI-1 expres-
sion in cell culture studies (21). In contrast, other reports
have suggested that the AT1 receptor does not mediate
AII-stimulated PAI-1 expression (49). However, recent
studies demonstrated the role of the AT1 receptor in
mediating the effects of AII on PAI-1 expression
(19,20,50). Furthermore, unlike losartan, candesartan abol-
ished the stimulatory action of AII on PAI-1 expression
(19,50). In human studies the effect of losartan on PAI-1
antigen remains controversial. For example, Erdem et al.
(33) reported that losartan and perindopril significantly
reduced PAI-1 antigen levels in patients with hypertension.
Goodfield et al. (34) reported that, in patients with heart
failure, losartan 50 mg, but not enalapril, reduced PAI-1
levels. In contrast, other studies demonstrated that losartan
did not change in patients (32,51–53). The effect of cande-
sartan on PAI-1 antigen is controversial. In postmenopausal
women, candesartan 8 mg daily for 12 weeks significantly
increased plasma PAI-1 antigen (32). However, in hyper-
cholesterolemic patients, candesartan 16 mg daily for six
weeks significantly decreased plasma PAI-1 antigen (30,31).
This discrepancy may result from the duration of treatment,
the patient population, and the drug dosage.
On the other hand, the complete blockade of AII-
induced PAI-1 expression by candesartan may be attributed
to its higher affinity and slower dissociation kinetics than
losartan (54,55). Thus, candesartan reduces maximal AII
binding to the AT1 receptor, whereas losartan causes a
rightward shift in the AII dose response without reducing
maximal AII binding (55). It is therefore likely that the
partial reduction of AII-induced PAI-1 expression by lo-
sartan (21) was due to incomplete antagonism of the AT1
receptor. In this regard, we observed that candesartan 16 mg
daily for eight weeks significantly reduced plasma levels of
PAI-1 antigen. Further, of the six postmenopausal women
in our study, five showed candesartan-induced reduction in
PAI-1 antigen levels relative to baseline values. The mean
reduction of PAI-1 antigen levels in all six were similar to
the effect of candesartan in all 45 patients (27% vs. 21%).
Several studies hypothesized that the effects of AT1
receptor blockers on endothelial function go beyond the
reduction of BP (1,24,30,56). We observed that candesartan
changed the percent flow-mediated dilator response to
hyperemia and serological markers of oxidant stress, inflam-
mation, and fibrinolysis independent of lowering BP.
In summary, we observed that candesartan therapy in
hypertensive patients reversed endothelial dysfunction,
measured as an improvement in flow-mediated dilation and
fibrinolysis and reduction of oxidant stress and inflamma-
tory cytokines independent of BP changes, suggesting that
AT1 receptor blocker therapy has antiatherogenic effects.
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